Bellicum Pharmaceuticals, Inc (BLCM): Kevin M. Slawin , Chief Technology Officer of Bellicum Pharmaceuticals, Inc sold 55,000 shares on Apr 22, 2016. The Insider selling transaction was reported by the company on Apr 26, 2016 to the Securities and Exchange Commission. The shares were sold at $11.58 per share for a total value of $628,498.38 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jan 6, 2016, Annemarie Moseley (COO/EVP Clinical Development) sold 35,000 shares at $19.48 per share price.On Dec 3, 2015, David M. Spencer (Chief Scientific Officer) sold 5,000 shares at $22.95 per share price.Also, On Nov 27, 2015, Alan A Musso (CFO and Treasurer) sold 29,300 shares at $22.34 per share price.On Nov 18, 2015, Kevin M. Slawin (Chief Technology Officer) sold 24,000 shares at $20.65 per share price.
Bellicum Pharmaceuticals Inc: On Friday, Apr 22, 2016 heightened volatility was witnessed in Bellicum Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $11.42 and hit $11.96 on the upside , eventually ending the session at $11.5, with a gain of 1.32% or 0.15 points. The heightened volatility saw the trading volume jump to 7,95,826 shares. The 52-week high of the share price is $29.33 and the company has a market cap of $310 M . The 52-week low of the share price is at $7.24.
Company has been under the radar of several Street Analysts.Bellicum Pharmaceuticals Inc is Initiated by Citigroup to Neutral and the brokerage firm has set the Price Target at $11. The Rating was issued on Feb 25, 2016.
Bellicum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer including hematological cancers and solid tumors as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy including hematopoietic stem cell transplantation (HSCT) chimeric antigen receptors (CAR) T cells therapy and dendritic cell vaccines. The Company’s product candidates include BPX-501 BPX-201 BPX-401 BPX-601 and BPX-701. It is also engaged in other development programs such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.